

Approval granted for the world's first, commercially available, fully closed-loop algorithm designed to run without carb counting or meal boluses

Cambridge, UK, 8 January 2026 – Following approval from its notified body, CamDiab Ltd announces its latest innovation that will allow users to manage their type 1 diabetes without needing to count carbohydrates or give pre-meal insulin.

This latest innovation will be the world's first, commercially available, automated insulin delivery algorithm to enable people living with type 1 diabetes to utilise a fully closed-loop system. A fully closed-loop algorithm removes the need for users to count carbohydrates and deliver pre-meal insulin. It looks to reduce day-to-day decision burden and give users a welcome break from some of the mental load related to managing their diabetes.¹

A pilot using this fully closed-loop algorithm is planned for early 2026, with wider roll-out to follow.

"We are delighted to receive approval, which represents a significant step forward, introducing fully closed-loop insulin delivery into routine type 1 diabetes care. By removing the need for carb counting and pre-meal bolusing, we can meaningfully reduce diabetes distress and the relentless cognitive load associated with living with type 1 diabetes. This innovation mirrors our commitment to developing technology that not only improves clinical outcomes but also enhances everyday life," said Professor Roman Hovorka, Director at CamDiab.

"I did not have to do anything. Which was fantastic. And it just made my life so so much easier... I just felt I was on a holiday when I was on that," said a study participant (2024)¹.

About CamDiab Ltd

CamDiab Ltd is a digital health and personalised medicine company focused on the design, development, and commercialisation of its world leading, interoperable CamAPS® FX closed-loop app. CamAPS® FX is designed to use an adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives.

Find out more at www.camdiab.com, or connect with us on [Facebook](#), [Instagram](#), [LinkedIn](#), [X](#), and [YouTube](#).

¹Lakshman R, Hartnell S, Ware J, Allen JM, Wilinska ME, Nwokolo M, et al. Lived experience of fully closed-loop insulin delivery in adults with type 1 diabetes. *Diabetes Technol Ther.* 2024 Apr;26(4):211-221

SOURCE: CamDiab Ltd

For further information:

CamDiab Media – Martin Ashcroft, media@camdiab.com